评估蜜蜂花粉通过其植物来源,总含量和微生物负载的特征,以配制药物治疗产品
Aysan Rezazadeh1, Ahmad Reza Mehrabian2,3, Hadi Maleki4
1Department of Cell and Molecular Biology, Faculty of Life Sciences and Biotechnology, Shahid Beheshti University, Tehran, Iran.
PloS one
|September 17, 2025
概括
这项研究分析了伊朗蜜蜂花粉 (BP) 的治疗特性. 特定植物家族的较高水平,比如Brassicaceae,与BP中总含量 (TPC) 的增加相关,这对其健康益处至关重要.
科学领域:
- 食品科学 食品科学 食品科学
- 植物学 植物学
- 分析化学 分析化学
背景情况:
- 蜜蜂花粉 (BP) 是一种有价值的蜂巢产品,具有公认的治疗特性.
- 了解BP的植物起源和化学成分对于质量评估至关重要.
研究的目的:
- 评估来自伊朗的38个蜜蜂花粉样本的植物来源,总含量 (TPC) 和微生物负载.
- 为了建立一个标准化伊朗蜜蜂花粉的基准.
主要方法:
- 植物起源通过扫描电子显微镜 (SEM) 确定.
- 使用Folin-Ciocalteu方法量化的总含量 (TPC).
- 通过盘数阿加尔 (PCA) 评估的总有氧化介质.
主要成果:
- 大多数样本是单花的,代表23个植物家族.
- 在TPC和Asteraceae,Brassicaceae,Rosaceae和Caryophyllaceae家族的丰富性之间发现了积极的相关性,而Brassicaceae表现出最强的影响.
- 平均TPC为18.48±1.97毫克GAE/g,平均总有氧性介质素为23,668.12 CFU/g.
结论:
- 该研究为标准化伊朗蜜蜂花粉提供了初步数据.
- 研究结果强调了植物来源,含量和微生物质量之间的联系,这与人类消费标准有关.
相关概念视频
Biopharmaceutical Factors Influencing Drug Product Design: Overview
Rational drug product design integrates knowledge of the drug’s physicochemical properties, formulation components, manufacturing techniques, and intended route of administration. Each factor influences the drug’s performance, including how it is released, absorbed, and eliminated in the body.The physicochemical properties of a drug—such as solubility, stability, and particle size—affect its compatibility with excipients and the choice of dosage form. Excipients, though pharmacologically...
Pharmaceutical Alternatives: Excipients and Impurities-Related Therapeutic Nonequivalence
Pharmaceutical products contain more than just the active drug; they also contain various excipients such as binders, solubilizers, stabilizers, preservatives, and other elements. In some cases, impurities or contaminants might be present. Traditionally, quality control in pharmaceuticals has primarily focused on the analysis of the active drug, often overlooking the impact of these additional components. The recent issue with heparin contamination by over-sulfated chondroitin sulfate, a...
Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence
Changes in polymorphic forms can significantly influence the bioavailability of poorly soluble drugs. Although the FDA defines pharmaceutical equivalence based on having the same active ingredient, dosage form, and route of administration, it does not automatically disqualify products with different polymorphic forms. This means two products with different polymorphs can still be deemed pharmaceutically equivalent. However, polymorphic differences can affect properties like wettability,...


